Appearance of Psoriasis after Tumor Necrosis Factor-alpha Blocker and Use of Ustekinumab or Tocilizumab for Refractory Monoarthritis.
10.4078/jrd.2015.22.4.263
- Author:
Jinyoung MOON
1
;
Nakwon KWAK
;
Jin LIM
;
Dong Jin GO
;
Jae Hyun LEE
;
Jin Kyun PARK
;
Eun Bong LEE
;
Yeong Wook SONG
;
Jai Il YOUN
;
Eun Young LEE
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. elee@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Tumor necrosis factor-alpha blocker;
Monoarthritis;
Psoriasis;
Ustekinumab;
Tocilizumab
- MeSH:
Arthralgia;
Arthritis, Psoriatic;
Arthritis, Rheumatoid;
Humans;
Inflammatory Bowel Diseases;
Interleukin-17;
Interleukin-6;
Joints;
Knee Joint;
Psoriasis*;
Receptors, Interleukin-6;
Skin;
Spondylitis, Ankylosing;
Synovial Fluid;
Tumor Necrosis Factor-alpha*;
Ustekinumab
- From:Journal of Rheumatic Diseases
2015;22(4):263-268
- CountryRepublic of Korea
- Language:English
-
Abstract:
Nowadays, tumor necrosis factor-alpha (TNF-alpha) blockers are used for treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Paradoxically, there are some reports on the appearance of psoriasis after administration of TNF-alpha blockers. Here, we report on a patient with monoarthritis in a knee joint who experienced psoriasis after TNF-alpha blocker therapy (adalimumab and etanercept). Oral medication was not a treatment option due to patient intolerance; thus, we tried ustekinumab, an anti-interleukin (IL)-12/23 monoclonal antibody used for treatment of psoriasis. Following ustekinumab injection, psoriatic skin lesions and joint symptoms were much improved. However, in the following period, joint pain and swelling became aggravated and synovial fluid cytokine levels including IL-6 and IL-17 were elevated. The treatment was changed to tocilizumab, a humanized monoclonal antibody against IL-6 receptor. After injection, knee joint swelling rapidly subsided without worsening of psoriatic skin lesions.
